-
DOJ charges 324 defendants in largest healthcare fraud initiative in its history
The collaborative Takedown effort targeted healthcare fraud that victimizes patients, taxpayers and government programs.
-
DOJ and HHS announce False Claims Act Working Group
Collaboration aims to advance both departments’ priority enforcement areas by sharing resources in pursuing False Claims Act violations.
-
CVS Caremark’s $95m penalty for Medicare drug overbilling
Whistleblower alleged Caremark reported higher costs of drugs to the government than it paid pharmacies for dispensing Medicare Part D drugs.
-
Trump administration uses False Claims Act to pursue anti-DEI goals
An investigation into Harvard’s admissions policies and a DOJ memo demonstrate how the False Claims Act could be deployed to crack down on DEI.
-
UnitedHealth Group under DOJ criminal fraud investigation, reports WSJ
The reported investigation follows a civil probe by the DOJ into the company’s controversial Medicaid billing practices.
-
Assertio Therapeutics dinged $3.6m over fentanyl false claims
The settlement is the latest in a string of False Claims Act enforcement actions against pharmaceutical companies.
-
Pharma conference digs into Gilead case, executive orders, CMS audits
At the annual pharmaceutical compliance event, speakers discussed the Gilead False Claims Case and Trump administration initiatives.
-
Pharmaceutical Compliance Congress: Panelists spot trends to prioritize in 2025
At the annual pharmaceutical compliance event, panelists said the time for an empowered compliance department engaged in mindful monitoring is now.